Feature | Breast Imaging | October 04, 2017 | By Melinda Taschetta-Millane

The Advancement of ABUS Technology

This article originally ran as an introduction to the ABUS comparison chart in the October 2017 issue. The chart can be viewed here.

The Siemens Acuson

The Siemens Acuson

GE Invenia ABUS

GE Invenia ABUS

Hitachi Sofia With Arietta 70

Hitachi Sofia With Arietta 70

The SonoCiné automated whole breast ultrasound (AWBUS)

The SonoCiné automated whole breast ultrasound (AWBUS)

 

 

According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent compound annual growth rate (CAGR) from 2017-2024, driven by rising incidence of breast cancer and volume scanner segment dominating this growth.

The report states that the global automated breast ultrasound system market will exceed $2 billion by 2024 as growing awareness through various programs and favorable government initiatives fuel this industry growth. It cites that ABUS held more than 45 percent of industry share in 2015, increasing product penetration thanks to its improved diagnostic capabilities that will stimulate industry demand. The U.S. market led the regional industry, due in part to an increased prevalence and adoption of advanced breast screening technologies. The report predicts that favorable government initiatives, reimbursement scenarios and the presence of leading market players will stimulate automated breast ultrasound system market growth.

The introduction of advanced technologies has made it possible to detect small cancer tumors as well as improve dense breast tissue scanning, and much of this technology has gained popularity due to its noninvasive, radiation-free and 3-D imaging features for breast cancer diagnosis. According to a new research report by Global Market Insights Inc.,2 this will help drive ABUS market growth.

New technologies are being introduced by some of the industry’s key players.

 

GE Invenia ABUS

GE Healthcare introduced its ABUS system, Invenia, back in 2013 at the Radiological Society of North America (RSNA) annual meeting. The system can conduct a whole-breast 3-D examination in 15 minutes, capturing thousands of images to provide a comprehensive view of the breast. Images are presented in the coronal view by default, but the more traditional views can be accessed with a single click. The company released a software update in March designed to improve image quality by enhancing tissue penetration, which reduces shadowing on the image.

 

Hitachi Sofia With Arietta 70

Hitachi Aloka became the exclusive distributor of iVu Imaging’s Sofia automated whole breast ultrasound scanner in 2014. The system can perform a whole-breast scan in 30 seconds, acquiring 900 images in a single sweep thanks to radial scan capabilities and an extra-long linear probe. Unlike other breast ultrasound systems, Sofia performs exams in the prone position.

In September 2016, Hitachi announced that the Sofia whole-breast imaging technology would be integrated with its own Arietta 60 and 70 ultrasound systems. The Arietta platform and its long linear transducer enable the system to automate the 3-D radial acquisition of an entire breast in nearly half the time of previous-generation ultrasound systems.

 

Siemens Acuson S2000 ABVS Ultrasound System Helx Evolution

The Acuson S2000 automated breast volume scanner (ABVS) system combines the power of 2-D/3-D ultrasound and advanced technologies, such as ultrasound elastography and multimodality review, with automated acquisition and intelligent workflow solutions to create one comprehensive package for breast ultrasound. According to the Global Markets Insights report, automated breast volume scanner (ABVS) is identified to be fastest growing segment, and is projected to exceed $700 million by 2024. The combination of ABVS with mammography allows both detection and evaluation of the breast cancers, accelerating the automated breast ultrasound system market growth over future years.

 

SonoCiné

The SonoCiné automated whole breast ultrasound (AWBUS) provides a consistent, repeatable scan of the whole breast, including the axilla. It connects to any ultrasound, taking advantage of the latest imaging technology. It is comfortable for the patient, requiring no compression.

In 2016, the company released 3-D whole breast multiplanar reconstruction software to improve early detection of breast cancer. This software package augments existing SonoCiné technology for high-resolution transverse imaging. The package offers viewing in three dimensions and it maintains the high-resolution transverse view, while adding the coronal and sagittal views.

 

Automated Breast Ultrasound Systems Comparison Chart

This article originally ran as an introduction to the ABUS comparison chart in the October 2017 issue. The chart can be viewed here. It will require a login, but it is free and only takes a minute to fill in the form.

 

References:

1.     “Automated Breast Ultrasound System Market will see 21% CAGR During 2017-2024 Dominated by Volume Scanners.” www.abnewswire.com/pressreleases/automated-breast-ultrasound-system-market-will-see-21-cagr-during-20172024-dominated-by-volume-scanners_131360.html. Accessed Sept. 19, 2017.

2.     “Industry Analysis For The Automated Breast Ultrasound Market.” www.gminsights.com/industry-analysis/automated-breast-ultrasound-market. Accessed Sept. 19, 2017.

Related Content

Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...
Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
News | Breast Imaging | January 04, 2021
January 4, 2021 — Smart Breast Corporation (SmartBreast), a privately held company focused on...